Karen Rowland Yeo

Dose Optimization Informed by PBPK Modeling: State-of-the Art and Future.

Karen Rowland Yeo, Eva Gil Bergland, Yuan Chen, 2024, Clinical pharmacology and therapeutics.

Use of Developmental Midazolam and 1-Hydroxymidazolam Data with Pediatric Physiologically Based Modeling to Assess Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyl Transferase 2B4 Ontogeny In Vivo

E. Howgate, K. Rowland Yeo, M. Turner, 2023, Drug Metabolism and Disposition.

Risk–Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach

K. Rowland Yeo, S. Neuhoff, I. Gardner, 2018, Clinical pharmacology and therapeutics.

Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam.

M. Jamei, G. Tucker, A. Rostami-Hodjegan, 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Modeling and predicting drug pharmacokinetics in patients with renal impairment

M. Jamei, A. Rostami-Hodjegan, K. Rowland Yeo, 2011, Expert review of clinical pharmacology.

Using physiologically‐based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet

L. V. von Moltke, K. Rowland Yeo, Z. Barter, 2021, CPT: pharmacometrics & systems pharmacology.

Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations

B. Small, K. Rowland Yeo, T. Johnson, 2022, CPT: pharmacometrics & systems pharmacology.